Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07737704
Recruiting Phase 2/3

Assessment of a New Enhanced Xenograft in Open Maxillary Sinus Augmentation

NCT07737704 · tracked via the Priya Life Science Egypt tracker
Sponsor
Misr International University
Phase
Phase 2/3
Started
2026-08-10
Last updated
2026-07-30

Condition(s) studied

Maxillary Sinus Floor AugmentationMaxillary Sinus ElevationBone Augmentation

Investigational drug(s) / intervention(s)

Xenograft →maxillary sinus membrane elevation and stabilization.

Xenograft: hydrogel-enhanced xenograft

maxillary sinus membrane elevation and stabilization.: graftless augmentation of the maxillary sinus floor through membrane elevation and stabilization; tenting.

Study summary

Implant supported dental restorations are sometimes challenging with decreased bone height in the posterior maxilla. The goal of this study is to test an augmentation bone substitute in elevating the maxillary sinus floor; in terms of soft tissue reaction, formed bone height as well as structure.

Bone substitute will be compared to a graftless method of bone augmentation depending on participants' bodies forming bone in the defective area.

Participants will:

* Undergo lateral maxillary sinus floor elevation with bone substitute or graftless method.
* Record postoperative swelling and pain through the follow up period.
* Take radiographs for evaluation of the formed bone before placing dental implants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adult male/female patients above the age of 18. * Patients with one or more teeth requiring implant supported dental restoration in atrophic posterior maxilla. * Alveolar bone height less than 5 mm at the defective site. * Good oral hygiene. * Patient's consensual agreement to be enrolled in the study. Exclusion Criteria: * Medically compromised patients with conditions contraindicating surgery (eg. uncontrolled diabetics, bisphosphonate intake, radio or chemotherapy). * Patients with active infection at or related to the site of surgery (eg. acute sinusitis). * Heavy smokers. * Patients not indicated for an implant supported restoration at the time of enrollement. (Patients developing any medical condition that interferes with the outcomes after enrolment in the study will be excluded).

Primary outcome measure(s)

  • bone height gain — 8 months
    radiographically, through CBCT

Trial sites (3)

FacilityCityRegionStatus
Suez Canal University Ismailia Ismailia Governorate Recruiting
Suez Canal University Ismailia Egypt Recruiting
Suez Canal University Ismailia Egypt Recruiting

More Misr International University trials in Egypt

Dimensional Changes Following Immediate Implant Placement in Molar Extraction Sockets With or Without Bone Graft Recruiting
Comparison of Immediate Implant Placement With Titanium Mesh Versus Collagen Membrane in Type II Socket: Recruiting
Novel Technique Versus Conventional Subepithelial Connective Tissue Graft in Treatment of Ridge Contour Defects Recruiting
Gingival Recession (RT1) Treatment With Different Gingival Augmentation Surgeries Recruiting
The Role of the Pre-operative Condition and Artificial Intelligence-Assisted Diagnosis in Predicting the Success of Full Pulpotomy in Symptomatic Permanent Mature Molars Recruiting

Other trials for the same condition

One Stage Ridge Splitting Using 2 Different Techniques in Maxilla Recruiting
Comparison of Immediate Implant Placement With Titanium Mesh Versus Collagen Membrane in Type II Socket: Recruiting
One Stage Ridge Splitting Using 2 Different Techniques in the Posterior Mandible Recruiting
Reconstruction of Deficient Atrophic Ridges Using Guide Bone Regeneration Technique Recruiting
Osseodensification Versus Osteotome Internal Sinus Lifting in Delayed Implant Placement Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07737704 on ClinicalTrials.gov ↗ ← All trials in Egypt